跳至主要内容
临床试验/NCT05093725
NCT05093725Unknown不适用

CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage

Sohag University1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2021年11月最近更新:
适应症

试验速览

阶段
不适用
入组人数
10
试验地点
1
主要终点
evaluation the best passage of MSC culture by CD49 surface marker

研究概览

简要总结

Human mesenchymal stem cells (MSCs) due to their regenerative and immunomodulatory properties are widely used for the treatment of bone and cartilage damage, cardiovascular, gastrointestinal, autoimmune, neurodegenerative diseases and cancer .It is shown that the use of MSCs in therapy is safe and can be effective .In 2006, the International Society for Cellular Therapy (ISCT) proposed the minimal criteria to define human MSCs. First, MSCs must be plastic-adherent when maintained in the standard culture conditions. Second MSCs must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
1 Day 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • normal babies delivered by normal labor

排除标准

  • diseased or congenital anomalies

结局指标

主要结局

evaluation the best passage of MSC culture by CD49 surface marker

时间窗: 7 months

evaluation the best passage of MSC culture by CD49 surface marker

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

samia samir shawky

resident doctor at clinical pathology in Sohag oncology center

Sohag University

研究点 (1)

Loading locations...

相似试验

CD49 in Optimization The Cologenicity of Mesenchymal... | 临床试验